CN102725000B - 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体 - Google Patents

靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体 Download PDF

Info

Publication number
CN102725000B
CN102725000B CN201080061420.0A CN201080061420A CN102725000B CN 102725000 B CN102725000 B CN 102725000B CN 201080061420 A CN201080061420 A CN 201080061420A CN 102725000 B CN102725000 B CN 102725000B
Authority
CN
China
Prior art keywords
igf
antibody
seq
cancer
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080061420.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102725000A (zh
Inventor
C·H·张
M·J·洛斯曼
D·M·戈德堡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of CN102725000A publication Critical patent/CN102725000A/zh
Application granted granted Critical
Publication of CN102725000B publication Critical patent/CN102725000B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201080061420.0A 2010-01-19 2010-03-12 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体 Active CN102725000B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2010/021345 2010-01-19
US2010021345 2010-01-19
PCT/US2010/027155 WO2011090492A1 (en) 2010-01-19 2010-03-12 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)

Publications (2)

Publication Number Publication Date
CN102725000A CN102725000A (zh) 2012-10-10
CN102725000B true CN102725000B (zh) 2015-10-07

Family

ID=44307101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080061420.0A Active CN102725000B (zh) 2010-01-19 2010-03-12 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体

Country Status (7)

Country Link
EP (2) EP3075390A1 (https=)
JP (1) JP5786204B2 (https=)
CN (1) CN102725000B (https=)
AU (1) AU2010343304B2 (https=)
CA (1) CA2787074A1 (https=)
IN (1) IN2012DN05101A (https=)
WO (1) WO2011090492A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
CA2855566A1 (en) 2011-12-02 2013-06-06 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2015097536A2 (en) * 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
MX375669B (es) * 2014-09-26 2025-03-06 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
KR20230119259A (ko) 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
CA3032775C (en) * 2016-08-16 2024-01-23 National Institute Of Advanced Industrial Science And Technology Malignant tumor target peptide
WO2018204872A2 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
MA48861A (fr) 2017-05-05 2020-04-01 Fusion Pharmaceuticals Inc Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CN113061191B (zh) * 2021-03-17 2023-03-24 托比康尔生物科技(武汉)有限公司 一种IgG样三功能抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291088A1 (en) * 2008-04-11 2009-11-26 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7329745B2 (en) * 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
EP1544291A4 (en) * 2002-07-19 2006-08-02 Towa Kagaku Co Ltd A NEW METHOD FOR THE PRODUCTION OF ANTIBODY CYME, NEW ANTIBODY CYM AND USE THEREOF
JP2007528201A (ja) * 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2277916A3 (en) * 2005-07-28 2011-04-27 Novartis AG Use of antibody to M-CSF
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291088A1 (en) * 2008-04-11 2009-11-26 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds

Also Published As

Publication number Publication date
IN2012DN05101A (https=) 2015-10-23
AU2010343304A1 (en) 2012-07-05
AU2010343304B2 (en) 2013-06-20
CA2787074A1 (en) 2011-07-28
JP5786204B2 (ja) 2015-09-30
CN102725000A (zh) 2012-10-10
JP2013516996A (ja) 2013-05-16
WO2011090492A1 (en) 2011-07-28
EP3075390A1 (en) 2016-10-05
EP2525820A1 (en) 2012-11-28
EP2525820A4 (en) 2013-08-21
EP2525820B1 (en) 2016-05-11

Similar Documents

Publication Publication Date Title
US10377829B2 (en) Isolated nucleic acid encoding an anti-IGF-1R antibody
CN102725000B (zh) 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体
AU2009282830B2 (en) Dock-and-lock (DNL) vaccines for cancer therapy
US9272057B2 (en) Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
CA2782194C (en) Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
EP2785382B1 (en) Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
CN102596235A (zh) 显示有效细胞毒活性的包含豹蛙酶(rap)的免疫毒素的组合物和使用方法
US8883162B2 (en) Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20180079816A1 (en) Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors
AU2010286496B2 (en) Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant